David J. Carlson
Research & Publications
Biography
News
Locations
Research Summary
The overall goal of my research is to develop more accurate radiobiological dose-response models that will advance biologically-guided radiation therapy (BGRT) for cancer patients. I hope to make scientific contributions to improve our basic understanding of the underlying physical and biological mechanisms that govern radiation response. Specifically, in my recent research, I have quantified the effects of the spatial pattern of energy deposition by different types of radiation on the relative biological effectiveness of x-rays, protons, and carbon ions in achieving local tumor control. I have also examined the combined effects of cellular oxygen concentration and spatial energy deposition on DNA damage formation and processing and cell death. I have a broad background in radiation physics and radiation biology. As a doctoral candidate at Purdue University, I conducted research on the mechanisms of intrinsic radiation sensitivity and examined the effects of DNA damage repair, oxygen, and radiation quality (particle LET) on biological endpoints such as double-strand break formation and cell killing. As a physics resident at Stanford University, I obtained a comprehensive understanding of the clinical application of radiation for the treatment of malignant and benign disease. I continued my research in radiobiological modeling to develop more realistic models of tumor hypoxia based on radial oxygen diffusion from tumor vasculature and the impact on radiation response. I am currently focused on (1) developing non-invasive functional imaging tools to quantify the spatial and temporal distributions of tumor hypoxia in early-stage non-small cell lung cancer and (2) implementing methods of biological optimization in heavy ion radiotherapy.
Specialized Terms: Biological optimization of radiation therapy; Tumor hypoxia and reoxygenation effects; Proton and heavy ion radiotherapy; Functional imaging; DNA damage and repair; Motion management; 4D imaging and treatment strategies; Prostate cancer; Lung cancer
Extensive Research Description
Current and Past Research Supported by:
Agency: National Institute of Health (NIH)
ID #: 3UM1CA186689 (PI: LoRusso, P.)
Project: ViKTriY Early Clinical Trials Consortium
Role: Co-investigator
Agency: American Cancer Society (ACS)
ID #: 128352-RSG-15-197-01-TBG (PI: Bindra, R.)
Project: Pre-clinical development of Mibefradil as a novel glioma radiosensitizer
Role: Co-investigator
Agency: NIH/NIAID, The Dartmouth Physically-Based Biodosimetry Center for Medical Countermeasures Against Radiation (Dart-Dose CMCR) Pilot Program
ID #: Pilot grant from U19AI1091173 (Swartz, H.)
Grant Name: Comparing In Vivo biodosimetry with EPR to independent physical dosimetry methods
Role: PI
Agency: Biomedical Advanced Research and Development Authority (BARDA) within the U.S. Department of Health and Human Services
ID #: Subcontract #HHSO100201100024C from Dartmouth College
Project Name: In Vivo biodosimetry using electron paramagnetic resonance (EPR) spectroscopy
Role: PI
Agency: Yale Comprehensive Cancer Center (YCC)
Grant Name: Non-invasive imaging of tumor hypoxia in non-small cell lung cancer patients undergoing stereotactic body radiotherapy
Role: PI
Agency: American Cancer Society (ACS)
ID #: IRG-58-012-52
Grant Name: Modeling relative biological effectiveness and oxygen effects in x-ray, proton, and carbon ion radiotherapy
Role: PI
Coauthors
Research Interests
Biophysics; DNA Damage; Lung Neoplasms; Physics; Prostatic Neoplasms; Cell Hypoxia; Radiation Oncology; Heavy Ion Radiotherapy
Selected Publications
- Responses to the 2017 "1 Million Gray Question": ASTRO Membership's Opinions on the Most Important Research Question Facing Radiation Oncology.Dominello MM, Keen JC, Beck TF, Bayouth J, Knisely J, Carlson DJ, Mendonca MS, Mian O, Brock KK, Anscher M, Hugo G, Moros EG, Singh AK, Yu JB. Responses to the 2017 "1 Million Gray Question": ASTRO Membership's Opinions on the Most Important Research Question Facing Radiation Oncology. International Journal Of Radiation Oncology, Biology, Physics 2018, 102: 249-250. PMID: 30003995, DOI: 10.1016/j.ijrobp.2018.06.045.
- Quantification of Tumor Hypoxic Fractions Using Positron Emission Tomography with [18F]Fluoromisonidazole ([18F]FMISO) Kinetic Analysis and Invasive Oxygen Measurements.Kelada OJ, Rockwell S, Zheng MQ, Huang Y, Liu Y, Booth CJ, Decker RH, Oelfke U, Carson RE, Carlson DJ. Quantification of Tumor Hypoxic Fractions Using Positron Emission Tomography with [18F]Fluoromisonidazole ([18F]FMISO) Kinetic Analysis and Invasive Oxygen Measurements. Molecular Imaging And Biology : MIB : The Official Publication Of The Academy Of Molecular Imaging 2017, 19: 893-902. PMID: 28409339, PMCID: PMC5640490, DOI: 10.1007/s11307-017-1083-9.
- Rapid implementation of the repair-misrepair-fixation (RMF) model facilitating online adaption of radiosensitivity parameters in ion therapy.Kamp F, Carlson DJ, Wilkens JJ. Rapid implementation of the repair-misrepair-fixation (RMF) model facilitating online adaption of radiosensitivity parameters in ion therapy. Physics In Medicine And Biology 2017, 62: N285-N296. PMID: 28561011, DOI: 10.1088/1361-6560/aa716b.
- A radiobiological model of reoxygenation and fractionation effects.Guerrero M, Carlson DJ. A radiobiological model of reoxygenation and fractionation effects. Medical Physics 2017, 44: 2002-2010. PMID: 28273349, DOI: 10.1002/mp.12194.
- The impact of cobalt-60 source age on biologically effective dose in high-dose functional Gamma Knife radiosurgery.Kann BH, Yu JB, Stahl JM, Bond JE, Loiselle C, Chiang VL, Bindra RS, Gerrard JL, Carlson DJ. The impact of cobalt-60 source age on biologically effective dose in high-dose functional Gamma Knife radiosurgery. Journal Of Neurosurgery 2016, 125: 154-159. PMID: 27903196, DOI: 10.3171/2016.6.GKS161497.
- Biologically optimized helium ion plans: calculation approach and its in vitro validation.Mairani A, Dokic I, Magro G, Tessonnier T, Kamp F, Carlson DJ, Ciocca M, Cerutti F, Sala PR, Ferrari A, Böhlen TT, Jäkel O, Parodi K, Debus J, Abdollahi A, Haberer T. Biologically optimized helium ion plans: calculation approach and its in vitro validation. Physics In Medicine And Biology 2016, 61: 4283-99. PMID: 27203864, DOI: 10.1088/0031-9155/61/11/4283.
- Real-time Tumor Oxygenation Changes After Single High-dose Radiation Therapy in Orthotopic and Subcutaneous Lung Cancer in Mice: Clinical Implication for Stereotactic Ablative Radiation Therapy Schedule Optimization.Song C, Hong BJ, Bok S, Lee CJ, Kim YE, Jeon SR, Wu HG, Lee YS, Cheon GJ, Paeng JC, Carlson DJ, Kim HJ, Ahn GO. Real-time Tumor Oxygenation Changes After Single High-dose Radiation Therapy in Orthotopic and Subcutaneous Lung Cancer in Mice: Clinical Implication for Stereotactic Ablative Radiation Therapy Schedule Optimization. International Journal Of Radiation Oncology, Biology, Physics 2016, 95: 1022-1031. PMID: 27130790, DOI: 10.1016/j.ijrobp.2016.01.064.
- Fast Biological Modeling for Voxel-based Heavy Ion Treatment Planning Using the Mechanistic Repair-Misrepair-Fixation Model and Nuclear Fragment Spectra.Kamp F, Cabal G, Mairani A, Parodi K, Wilkens JJ, Carlson DJ. Fast Biological Modeling for Voxel-based Heavy Ion Treatment Planning Using the Mechanistic Repair-Misrepair-Fixation Model and Nuclear Fragment Spectra. International Journal Of Radiation Oncology, Biology, Physics 2015, 93: 557-68. PMID: 26460998, DOI: 10.1016/j.ijrobp.2015.07.2264.
- High-dose and fractionation effects in stereotactic radiation therapy: Analysis of tumor control data from 2965 patients.Shuryak I, Carlson DJ, Brown JM, Brenner DJ. High-dose and fractionation effects in stereotactic radiation therapy: Analysis of tumor control data from 2965 patients. Radiotherapy And Oncology : Journal Of The European Society For Therapeutic Radiology And Oncology 2015, 115: 327-34. PMID: 26058991, DOI: 10.1016/j.radonc.2015.05.013.
- Extension of TOPAS for the simulation of proton radiation effects considering molecular and cellular endpoints.Polster L, Schuemann J, Rinaldi I, Burigo L, McNamara AL, Stewart RD, Attili A, Carlson DJ, Sato T, Ramos Méndez J, Faddegon B, Perl J, Paganetti H. Extension of TOPAS for the simulation of proton radiation effects considering molecular and cellular endpoints. Physics In Medicine And Biology 2015, 60: 5053-70. PMID: 26061666, PMCID: PMC4511084, DOI: 10.1088/0031-9155/60/13/5053.
- Synthesis of [(18)F]FMISO in a flow-through microfluidic reactor: Development and clinical application.Zheng MQ, Collier L, Bois F, Kelada OJ, Hammond K, Ropchan J, Akula MR, Carlson DJ, Kabalka GW, Huang Y. Synthesis of [(18)F]FMISO in a flow-through microfluidic reactor: Development and clinical application. Nuclear Medicine And Biology 2015, 42: 578-84. PMID: 25779036, DOI: 10.1016/j.nucmedbio.2015.01.010.
- Is it the time for personalized imaging protocols in cancer radiation therapy?Zhang Y, Feng Y, Zhang Y, Ming X, Yu J, Carlson DJ, Kim J, Deng J. Is it the time for personalized imaging protocols in cancer radiation therapy? International Journal Of Radiation Oncology, Biology, Physics 2015, 91: 659-60. PMID: 25680605, DOI: 10.1016/j.ijrobp.2014.10.044.
- The tumor radiobiology of SRS and SBRT: are more than the 5 Rs involved?Brown JM, Carlson DJ, Brenner DJ. The tumor radiobiology of SRS and SBRT: are more than the 5 Rs involved? International Journal Of Radiation Oncology, Biology, Physics 2014, 88: 254-62. PMID: 24411596, PMCID: PMC3893711, DOI: 10.1016/j.ijrobp.2013.07.022.
- Molecular imaging of tumor hypoxia with positron emission tomography.Kelada OJ, Carlson DJ. Molecular imaging of tumor hypoxia with positron emission tomography. Radiation Research 2014, 181: 335-49. PMID: 24673257, PMCID: PMC5555673, DOI: 10.1667/RR13590.1.
- A molecular dynamics simulation of DNA damage induction by ionizing radiation.Abolfath RM, Carlson DJ, Chen ZJ, Nath R. A molecular dynamics simulation of DNA damage induction by ionizing radiation. Physics In Medicine And Biology 2013, 58: 7143-57. PMID: 24052159, DOI: 10.1088/0031-9155/58/20/7143.
- Dose escalation, not "new biology," can account for the efficacy of stereotactic body radiation therapy with non-small cell lung cancer.Brown JM, Brenner DJ, Carlson DJ. Dose escalation, not "new biology," can account for the efficacy of stereotactic body radiation therapy with non-small cell lung cancer. International Journal Of Radiation Oncology, Biology, Physics 2013, 85: 1159-60. PMID: 23517805, PMCID: PMC3608927, DOI: 10.1016/j.ijrobp.2012.11.003.
- A mechanism-based approach to predict the relative biological effectiveness of protons and carbon ions in radiation therapy.Frese MC, Yu VK, Stewart RD, Carlson DJ. A mechanism-based approach to predict the relative biological effectiveness of protons and carbon ions in radiation therapy. International Journal Of Radiation Oncology, Biology, Physics 2012, 83: 442-50. PMID: 22099045, DOI: 10.1016/j.ijrobp.2011.06.1983.
- Hypofractionation results in reduced tumor cell kill compared to conventional fractionation for tumors with regions of hypoxia.Carlson DJ, Keall PJ, Loo BW, Chen ZJ, Brown JM. Hypofractionation results in reduced tumor cell kill compared to conventional fractionation for tumors with regions of hypoxia. International Journal Of Radiation Oncology, Biology, Physics 2011, 79: 1188-95. PMID: 21183291, PMCID: PMC3053128, DOI: 10.1016/j.ijrobp.2010.10.007.
- Tumor hypoxia is an important mechanism of radioresistance in hypofractionated radiotherapy and must be considered in the treatment planning process.Carlson DJ, Yenice KM, Orton CG. Tumor hypoxia is an important mechanism of radioresistance in hypofractionated radiotherapy and must be considered in the treatment planning process. Medical Physics 2011, 38: 6347-50. PMID: 22149817, DOI: 10.1118/1.3639137.
- Effects of radiation quality and oxygen on clustered DNA lesions and cell death.Stewart RD, Yu VK, Georgakilas AG, Koumenis C, Park JH, Carlson DJ. Effects of radiation quality and oxygen on clustered DNA lesions and cell death. Radiation Research 2011, 176: 587-602. PMID: 21823972, DOI: 10.1667/rr2663.1.
- DMLC motion tracking of moving targets for intensity modulated arc therapy treatment: a feasibility study.Zimmerman J, Korreman S, Persson G, Cattell H, Svatos M, Sawant A, Venkat R, Carlson D, Keall P. DMLC motion tracking of moving targets for intensity modulated arc therapy treatment: a feasibility study. Acta Oncologica (Stockholm, Sweden) 2009, 48: 245-50. PMID: 18720056, DOI: 10.1080/02841860802266722.
- Management of three-dimensional intrafraction motion through real-time DMLC tracking.Sawant A, Venkat R, Srivastava V, Carlson D, Povzner S, Cattell H, Keall P. Management of three-dimensional intrafraction motion through real-time DMLC tracking. Medical Physics 2008, 35: 2050-61. PMID: 18561681, PMCID: PMC2809733, DOI: 10.1118/1.2905355.
- Combined use of Monte Carlo DNA damage simulations and deterministic repair models to examine putative mechanisms of cell killing.Carlson DJ, Stewart RD, Semenenko VA, Sandison GA. Combined use of Monte Carlo DNA damage simulations and deterministic repair models to examine putative mechanisms of cell killing. Radiation Research 2008, 169: 447-59. PMID: 18363426, DOI: 10.1667/RR1046.1.
- Effects of oxygen on intrinsic radiation sensitivity: A test of the relationship between aerobic and hypoxic linear-quadratic (LQ) model parameters.Carlson DJ, Stewart RD, Semenenko VA. Effects of oxygen on intrinsic radiation sensitivity: A test of the relationship between aerobic and hypoxic linear-quadratic (LQ) model parameters. Medical Physics 2006, 33: 3105-15. PMID: 17022202, DOI: 10.1118/1.2229427.
- Comparison of in vitro and in vivo alpha/beta ratios for prostate cancer.Carlson DJ, Stewart RD, Li XA, Jennings K, Wang JZ, Guerrero M. Comparison of in vitro and in vivo alpha/beta ratios for prostate cancer. Physics In Medicine And Biology 2004, 49: 4477-91. PMID: 15552412, DOI: 10.1088/0031-9155/49/19/003.